Tubal ligation and ovarian cancer risk in a large cohort: Substantial variation by histological type

Kezia Gaitskell, Jane Green, Kirstin Pirie, Gillian Reeves and Valerie Beral; on behalf of the Million Women Study Collaborators

Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom

Ovarian cancer is one of the most common causes of cancer death amongst women in high income countries. There is increasing evidence that the different histological subtypes (histotypes) of ovarian cancer may have different origins, and show different molecular signatures. The vast majority of ovarian cancers are epithelial tumours, of which the four most common histotypes are serous, mucinous, endometrioid and clear cell tumours. For serous tumours, it has been further suggested that they be divided into low-grade serous tumours (consisting of serous borderline tumours and low-grade serous carcinoma) and high-grade serous carcinoma.

Meta-analyses of observational epidemiological studies have consistently found that tubal ligation (also known as sterilization, in which the fallopian tubes are clipped, cut, or tied) is associated with an overall reduced risk of ovarian cancer. However, published findings by tumour histotype are inconsistent, except perhaps that most investigators have reported a reduced risk for endometrioid tumours. Epidermiological studies need to be sufficiently large to have enough power to detect reliably heterogeneity by tumour histotype. We therefore report here on the association observed between tubal ligation and incident ovarian cancer in a large cohort study of UK women.

Material and Methods

Study design, data collection and follow-up

The Million Women Study is a prospective study of 1.3 million UK women, recruited in 1996–2001 via the UK National Health Service (NHS) Breast Screening Programme. At recruitment, women completed a questionnaire on socio-demographic, reproductive, medical and lifestyle factors. The cohort is resurveyed approximately every 3 to 5 years. The
Tubal ligations can reduce ovarian cancer—but possibly only certain types. This large study reports on the risk of four main ovarian tumour histotypes following tubal ligation. They found that the procedure almost halved the risk of clear cell tumors and endometrioid tumours, but had little effect on mucinous tumours. For serous tumours, risk varied by grade: tubal ligation reduced the risk of high-grade, but not low-grade, serous tumours. These findings support the hypothesis that high- and low-grade serous tumours have different causes, and that some ovarian tumours may arise from cells or carcinogens travelling through the fallopian tubes.

study design and methods are described in detail elsewhere, and questionnaires can be viewed online at http://www.millionwomenstudy.org.

All participants have been flagged on the NHS Central Register (NHSCR), so the study investigators are routinely notified of cancer registrations and deaths. The information provided includes the date of the event (cancer registration or death), together with the cancer site (coded using the 10th revision of the International Classification of Diseases, ICD-10) and tumour morphology (coded using the second and third editions of the International Classification of Diseases for Oncology, ICD-O). The Million Women Study has also been linked to data from the National Cancer Intelligence Network (NCIN), providing additional information on diagnostic histology codes, and on tumour grade, for cases diagnosed in England. For this study, tumour histology and grade information from NCIN were used where available, to supplement the NHSCR data.

All participants gave written consent to follow-up at recruitment. Ethical approval was granted by the Oxford and Anglia Multi-Centre Research Ethics Committee (MREC 97/01).

Exposure variables
Women in the study were asked at recruitment “Have you been sterilised (had your tubes tied)?,” and if so, their age at sterilization (used for analyses of the timing of sterilization).

Outcome
The outcome of interest was ovarian cancer (C56 in ICD-10). For histotype analyses, the outcome was split into five histological groups: serous (ICD-O codes 8441–8442, 8451, 8460–8463, 9014), mucinous (ICD-O codes 8470–8490), endometrioid (ICD-O codes 8380–8381, 8560, 8570, 8933, 8950), clear cell (ICD-O codes 8310, 8313) and other.

For some exploratory analyses, tumour types were analysed separately by grade (available for about 40% of all cases). Three-tier grading systems had generally been used (including those outlined by FIGO (International Federation of Gynecology and Obstetrics), WHO (World Health Organization), and Silverberg), and the few cases classified as “grade 4” were grouped together with “grade 3” tumours.

Serous tumours were divided into low-grade tumours (defined here as borderline (ICD-O codes 8442, 8451, 8462, 8463) or grade 1 serous tumours), and high-grade serous carcinoma (defined here as grade ≥2 serous tumours). The assumptions we made in converting tumour grade information from the three-tier (grade 1–3) to the two-tier (low-grade vs. high-grade) system for serous carcinoma were in line with those used in other publications.

Endometrioid tumours were divided into two, i.e., grade 1 or 2, and grade 3, as it has been suggested that some high-grade (grade 3) endometrioid ovarian carcinomas might be the same as high-grade serous carcinomas and should be considered with them.

Clear cell tumours were not divided by grade, as all clear cell ovarian cancers are high-grade/grade 3, by definition.

Mucinous tumours were split into mucinous borderline tumours (ICD-O codes 8472–8473) and mucinous carcinoma (ICD-O codes 8470–8471 and 8480–8490); the mucinous carcinomas were not further subdivided by tumour grade, as numbers were small.

Statistical analysis
Women were excluded from the analyses if: (i) they had been diagnosed with any invasive cancer other than nonmelanoma skin cancer (ICD-10 code C44) prior to recruitment (n = 66,221), (ii) they reported at recruitment having had both ovaries removed (bilateral oophorectomy), or if they were unsure whether they had or not (n = 170,769), or (iii) they had missing data on tubal ligation (n = 15,712). The remaining women (N = 1,132,914) contributed person-years from the date of recruitment into the study until the date of registration for ovarian cancer, the date of death, or last date of follow-up (December 31, 2013)—whichever was soonest. Women were censored at diagnosis of any nonovarian cancer. For analyses exploring effects of the timing of tubal ligation, women were excluded if they had missing information on age at tubal ligation (n = 14,684). About 1% of participants had been lost to follow-up and such women are censored at the date when they were lost, contributing person-years until then.

Cox (proportional hazards) regression models were used to estimate hazard ratios [referred to as relative risks (RRs)] of developing ovarian cancer by tubal ligation status. Attained age was the underlying time variable. There was no evidence of significant violation of the proportional hazards assumption, as assessed by graphical methods and tests based on Schoenfeld residuals.

All analyses were stratified by geographical region (10 regions corresponding to the areas covered by the cancer
registries), and further adjusted for parity (0, 1, 2, 3+), use of the oral contraceptive pill (never, ever), family history of breast cancer (no, yes), hysterectomy (no, yes), use of menopausal hormones (never, ever), body mass index (BMI) (<25 kg/m², 25–29 kg/m², 30+ kg m⁻²), smoking history (never, past, current) and quintiles of socioeconomic status (based on the Townsend deprivation index). All adjustment variables were as reported at recruitment. For adjustment variables, missing values were assigned to a separate category. Exposure information was either missing or reported as unknown for 6% of women for all potential confounders. Sensitivity analyses were conducted excluding all women with missing data on covariates within the model.

Other factors (including alcohol consumption, physical activity and age at menarche) were explored as potential confounders, but were not included in the final model as their inclusion made no appreciable difference to the main estimate of effect.

Tests of heterogeneity in the relationship between tubal ligation and ovarian cancer risk by histotype were performed using a competing risks approach. Analyses were also conducted to explore possible effects of age and time with tubal ligation, including age at, time since and calendar year of tubal ligation, and whether the tubal ligation was in the same year as the last birth or afterward. All analyses of the timing of tubal ligation were restricted to parous women, as there were very few nulliparous women who had had a tubal ligation. Where comparisons are made between more than two exposure categories, group-specific confidence intervals for the log risk in each group were calculated, allowing comparisons to be made between any two categories, even if neither is the reference group.

Analyses were performed in Stata-14. Tests of statistical significance were two-sided. Figures were drawn in R using Matthew Arnold and Paul Sherliker’s “Jasper” package.

### Results

A total of 1,132,914 women, mean age at recruitment 56.1 [standard deviation (SD) 4.8] years, were included in the analyses. At recruitment, 246,048 (22%) reported having had a tubal ligation, at median age 35 [interquartile range (IQR) 31–38], and median year 1978 (IQR 1973–1982). Women who reported a previous tubal ligation were more likely to be parous, to have used the oral contraceptive pill and menopausal hormones, to have had a hysterectomy, to be a current smoker, and to live in areas in the lower third of

### Table 1. Characteristics of the study population at recruitment, and details of follow-up, by tubal ligation status

| Characteristics                        | Tubal ligation | All women |
|----------------------------------------|----------------|-----------|
|                                        | No             | Yes       |           |
| Number of women                        | 886,866        | 246,048   | 1,132,914 |
| Mean (SD) age at recruitment (years)   | 56.3 (4.9)     | 55.3 (4.3) | 56.1 (4.8) |
| Socioeconomic status, lower third, % (n) | 30.5 (268,314) | 38.0 (92,663) | 32.1 (360,977) |
| Mean age at menarche (SD)              | 13.0 (1.6)     | 13.0 (1.6) | 13.0 (1.6) |
| Nulliparous, % (n)                     | 13.3 (117,319) | 2.6 (6,352) | 10.9 (123,671) |
| Ever use of oral contraceptive pill, % (n) | 57.0 (501,857) | 70.3 (171,546) | 59.9 (673,403) |
| Ever use of menopausal hormones, % (n) | 44.5 (390,518) | 54.9 (133,529) | 46.7 (524,047) |
| Hysterectomy, % (n)                    | 14.2 (126,054) | 19.4 (47,579) | 15.4 (173,633) |
| Mean age at natural menopause (SD)     | 49.3 (4.2)     | 48.7 (4.5) | 49.1 (4.3)  |
| Family history of breast cancer, % (n) | 9.8 (82,101)   | 10.0 (22,781) | 9.9 (104,882) |
| Mean (SD) body mass index (kg/m²)      | 26.0 (4.6)     | 26.6 (4.8) | 26.1 (4.7)  |
| Current smoker, % (n)                  | 18.4 (153,773) | 26.4 (61,264) | 20.1 (215,037) |
| Strenuous exercise ≥ once/week, % (n)  | 39.8 (340,538) | 37.7 (89,266) | 39.3 (429,804) |
| Alcohol intake, ≥ 7 units/week, % (n)  | 23.6 (207,870) | 25.5 (62,130) | 24.0 (270,000) |

(continued...)

Means and percentages are calculated excluding missing values for the variable of interest.

n: number of women. SD: standard deviation.
socioeconomic status, compared to women without tubal ligation (Table 1).

The women were followed up for incident ovarian cancer over 15.6 million person-years, with a mean duration of follow-up of 13.8 (SD 3.4) years per woman. During this period, 8,035 incident ovarian cancers were registered, of which 3,515 (44%) were serous; 836 (10%) were mucinous; 690 (9%) were endometrioid; 401 (5%) were clear cell and 2,593 (32%) were of other histological types (mostly unspecified epithelial tumours). The mean age at diagnosis of ovarian cancer was 65.1 years (SD 6.4).

The relative risk of ovarian cancer amongst women with tubal ligation compared to those without was 0.80 (95% CI: 0.76–0.85, \( p < 0.001 \)), after adjustment for age, region, parity, family history of breast cancer, hysterectomy, use of the oral contraceptive pill and menopausal hormones, body mass index, smoking and socioeconomic status. Serous tumours have been split into low-grade (serous borderline tumours and low-grade serous carcinoma, here defined as grade 1) and high-grade (serous carcinoma of grade \( \geq 2 \)). Endometrioid tumours have been split into low-grade (here defined as grade 1–2) and high-grade (grade 3); see main text for discussion of rationale for this. Note: The numbers of grade-specific serous and endometrioid tumours do not sum to the total numbers of serous and endometrioid tumours, as information on tumour grade was missing for 1,475 serous carcinomas and 273 endometrioid carcinomas.

![Figure 1. Relative risk of subtypes of ovarian cancer in women with versus without a history of tubal ligation. \( N = 1,132,914 \). Results show relative risks (hazard ratios) of ovarian cancer amongst women with a history of tubal ligation compared to women without a history of tubal ligation, by histological subtype. Analyses are adjusted for age, region, parity, family history of breast cancer, hysterectomy, use of the oral contraceptive pill and menopausal hormones, body mass index, smoking and socioeconomic status. Serous tumours have been split into low-grade (serous borderline tumours and low-grade serous carcinoma, here defined as grade 1) and high-grade (serous carcinoma of grade \( \geq 2 \)). Endometrioid tumours have been split into low-grade (here defined as grade 1–2) and high-grade (grade 3); see main text for discussion of rationale for this. Note: The numbers of grade-specific serous and endometrioid tumours do not sum to the total numbers of serous and endometrioid tumours, as information on tumour grade was missing for 1,475 serous carcinomas and 273 endometrioid carcinomas.](https://example.com)
fully malignant mucinous carcinoma \( (n = 426, \text{RR: 1.01, 95\% CI: 0.79–1.29}) \).

A sensitivity analysis excluding all women with missing values in any of the adjustment variables showed that the association between tubal ligation and ovarian cancer, and the variation by histotype, was not appreciably changed (data not shown).

There was little or no variation in risk either by age at, year of, or years since tubal ligation, or whether tubal ligation was performed in the same year as the last birth or subsequently, for ovarian cancer overall, and for endometrioid and clear cell tumours (Fig. 2). Compared to women without tubal ligation, for serous tumours there was some suggestion of a greater reduction in risk with tubal ligations performed \( \leq 1974 \) (RR: 0.69, 95\% CI: 0.58–0.81), than with those performed in 1975–1979 (RR: 0.92, 95\% CI: 0.80–1.06), or those performed in 1980 or later (RR: 0.84, 95\% CI: 0.73–0.98), heterogeneity: \( p = 0.02 \). There was also some suggestion of a greater reduction in risk for women with a time since tubal ligation of \( > 25 \) years (RR: 0.77, 95\% CI: 0.69–0.85) than for \( \leq 25 \) years since tubal ligation (RR: 0.94, 95\% CI: 0.80–1.10), heterogeneity: \( p = 0.04 \).

There was no significant variation in the association between tubal ligation and ovarian cancer with parity, use of contraceptive or menopausal hormones, hysterectomy, age at natural menopause, family history of breast cancer, smoking, socioeconomic status, frequency of strenuous exercise or alcohol intake (Fig. 3). There was some weak evidence of heterogeneity by body mass index and age at menarche, although this may well be due to chance, as multiple statistical tests were performed.

**Discussion**

In a large prospective cohort study with 8,035 incident cases of ovarian cancer, we found strong evidence that the risk of ovarian cancer associated with tubal ligation varied by tumour histotype. We found a modest reduction in risk of the most common histotype, serous tumours, as had been previously reported.\(^7\)–\(^9\) However, when we split serous tumours into low-grade serous tumours and high-grade serous carcinoma, we found significant differences, with a 20\% reduction in risk of high-grade serous carcinoma, but no reduction in risk of low-grade serous tumours. This is the first study to report a significant difference between the risks of low-grade versus high-grade serous ovarian tumours associated with tubal ligation.

We found about a halving of the risk of endometrioid and of clear cell tumours associated with tubal ligation. Others have reported similar findings for endometrioid tumours.\(^7\)–\(^9\) Reported findings for clear cell tumours are mixed, perhaps because it is relatively uncommon. We found little or no association between tubal ligation and the risk of mucinous ovarian cancer, in keeping with some reports,\(^7\)–\(^8\) though not others.\(^9\)
New hypotheses about the origins of ovarian cancer have provoked a reconsideration of possible mechanisms underlying the reduced risk of ovarian cancer with tubal ligation. The significant heterogeneity seen here between low-grade versus high-grade serous tumours is consistent with the hypothesis that the two tumour subtypes develop along distinct pathways.

High-grade serous ovarian cancer is hypothesised to arise from precursor lesions within the fallopian tubal epithelium, particularly in the fimbrial end adjacent to the ovary, and subsequently seed to the ovary. There is considerable evidence for this, including several studies showing putative precursor lesions within the fallopian tubes (such as focal areas of epithelium featuring mutations in the tumour-suppressor...
gene TP53 or aberrant expression of its protein p53, and/or areas of dysplasia or intraepithelial serous carcinoma), not only in prophylactic salpingoophorectomy specimens from women with an increased genetic risk of ovarian cancer, and from women with known high-grade serous ovarian cancer,\textsuperscript{28–34} but also in salpingoophorectomy specimens from women not known to be at increased genetic risk, in some cases with accompanying incidental invasive high-grade serous carcinoma.\textsuperscript{35–37} The putative precursor lesions in many cases show molecular changes that are similar or identical to those seen in co-existing high-grade serous ovarian cancer, particularly in terms of TP53 mutations\textsuperscript{33} (mutations in the gene for p53 being characteristic and ubiquitous in high-grade serous ovarian cancer\textsuperscript{38}).

The origins of low-grade serous tumours are considerably more uncertain. In many cases, there appears to be a stepwise progression from ovarian epithelial inclusion cysts, through benign cystadenomas and serous borderline tumours, to low-grade serous carcinoma. Evidence for this includes the frequent co-existence of serous borderline tumours with low-grade serous carcinomas,\textsuperscript{18} and similar molecular changes: both serous borderline tumours and low-grade serous carcinomas commonly feature mutations in BRF or KRAS,\textsuperscript{39} but rarely in TP53,\textsuperscript{40} in contrast to high-grade serous carcinoma. It has been suggested that some low-grade serous tumours may also originate indirectly from tubal epithelial cells (perhaps from benign or hyperplastic tubal epithelial cells which become trapped in the ovary as epithelial inclusion cysts at the time of ovulation, possibly at a young age),\textsuperscript{41,42} but the evidence for this is much less established than that for the tubal origins of high-grade serous carcinoma.

Surgical ligation of the fallopian tube might reduce the risk of high-grade serous ovarian cancer, either by physically obstructing the passage of tubal cells toward the ovary, or by collateral damage to the local tubal blood supply, with potential subsequent effects on the tubal epithelium. In addition, some forms of tubal sterilization involve removal of some or all of the tube, and/or disruption of the distal end of the tube—which might have been more common in the past, and could possibly explain the significantly greater risk reduction found for tubal ligations done before than after 1974.

The apparent lack of an effect of tubal ligation for low-grade serous tumours is consistent with the hypothesis that they have a different origin to high-grade serous ovarian cancer. However, it is not entirely incompatible with a possible tubal origin for low-grade serous tumours (e.g., if the precursor cells of origin had already been attached to the ovary before the tubal ligation occurred).

Some endometrioid and clear cell tumours are thought to develop from endometriosis,\textsuperscript{3,4} and one might speculate that the almost halving of risk seen with tubal ligation could be due to the blocking of retrograde menstruation through the fallopian tubes to the ovaries and pelvis. It could also reflect the blocking of the transport of carcinogens up the tubes to the ovaries and pelvis. For any mechanism that involved the blockage of menstruation or the passage of carcinogens up the tube, one might expect the association with tubal ligation to vary by timing (e.g., a greater reduction in risk for tubal ligation performed at a younger age, or longer ago). However, we found no suggestion of any association with the timing of tubal ligation for ovarian cancer overall or for endometrioid and clear cell tumours, and only limited evidence of an association with the year of, and years since, tubal ligation for serous tumours. These findings are in keeping with most, but not all, previous studies.\textsuperscript{7–9}

Our study has several strengths, in addition to the large sample size and number of cases. In particular, the prospective collection of exposure data helped to prevent differential recall of tubal ligation or other factors amongst women with and without cancer. The use of routinely collected national data for follow-up and ascertainment of incident ovarian cancer resulted in few participants being lost to follow-up. The prospective study design also facilitated the involvement of women with more aggressive tumour types, who might not be included in retrospective studies, as there can be a substantial time lag between cancer diagnosis and recruitment to a retrospective study. The high prevalence of tubal ligation (22%) was also an advantage in terms of statistical power.

One potential weakness of our study was that we did not undertake central histopathological review of our cases, for standardization and incorporation of the latest diagnostic criteria. The distribution of histotypes amongst our cases was consistent with those from other population-based studies, with serous tumours accounting for around 65% of those of the four main histotypes, endometrioid tumours for 13%, mucinous 15%, and clear cell 7% (by way of comparison, the corresponding percentages from the EPIC cohort are: 67% serous, 13% endometrioid, 14% mucinous, and 6% clear cell\textsuperscript{33}). This distribution is slightly different to that reported by two hospital-based studies of ovarian cancer cases, in both of which mucinous tumours accounted for only around 3% of cases\textsuperscript{44,45}; this may reflect differences in the study populations (North America vs. Europe), or historical differences in diagnostic criteria (e.g., mucinous tumours in our cohort might include some metastases from the gastrointestinal tract).

About 32% of ovarian cancers in our study were not recorded as being of one of the four main histotypes (serous, endometrioid, clear cell or mucinous). Of these, 87% were epithelial tumours of other, mixed, or unspecified type (mostly unspecified adenocarcinoma, ICD-O code 8140, or unspecified carcinoma, ICD-O code 8010), and 10% were unspecified malignant tumours (ICD-O code 8000). Given that high-grade serous carcinoma is the most common histotype of ovarian cancer, it seems likely that many of the tumours listed as unspecified carcinoma/adenocarcinoma are in fact high-grade serous tumours. This would be supported by our observation that tubal ligation is associated with a similar reduction in risk of other/unspecified ovarian cancer (RR: 0.80, 95% CI: 0.71–0.89) as of high-grade serous carcinoma (RR: 0.77, 95% CI: 0.67–0.89).
Tumour histology may have been classified in somewhat different ways by different pathologists. Any such misclassification would tend to blur differences by tumour histotype, yet distinctly heterogeneous risks were found. This argues strongly for causality, as it confirms that the variation in risk associated with tubal ligation is not just due to confounding, and strengthens hypotheses that different histotypes of ovarian cancer have different causes.

Acknowledgements
The authors thank all the women who participated in the Million Women Study, and the staff from the NHS Breast Screening Centres. They also thank the anonymous reviewers for their very helpful comments and suggestions. Some of these results were presented in preliminary form at the National Cancer Research Institute Cancer Conference, 2014 (Liverpool, UK). This work was supported by Cancer Research UK (CRUK) grant number C38302/A17318, through a CRUK Oxford Centre Clinical Research Training Fellowship for KG.

Million Women Study Collaborators

Million Women Study Co-ordinating Centre staff: Hayley Abbiss, Simon Abbott, Rupert Alison, Naomi Allen, Miranda Armstrong, Krys Baker, Angela Balkwill, Emily Banks, Isobel Barnes, Valerie Beral, Judith Black, Roger Blanks, Kathryn Bradbury, Anna Brown, Benjamin Cairns, Karen Canfell, Dexter Canoy, Andrew Chadwick, Barbara Crossley, Francesca Crowe, Dave Ewart, Sarah Ewart, Lee Fletcher, Sarah Floud, Toraal Gathani, Laura Gerrard, Adrian Goodill, Jane Green, Lynden Guiver, Michel Hozak, Isobel Lingard, Sau Wan Kan, Oksana Kirichek, Nicky Langston, Bette Liu, Kath Moser, Kirstin Pirie, Gillian Reeves, Keith Shaw, Emma Sherman, Helena Strange, Sian Sweetland, Sarah Tipper, Ruth Travis, Lyndsey Trickett, Lucy Wright, Owen Yang, Heather Young.

Million Women Study Advisory Committee: Emily Banks, Valerie Beral, Lucy Carpenter, Carol Dezateux, Jane Green, Julietha Patnick, Richard Peto, Cathie Sudlow.

The NHS Breast Screening Centres which took part in the recruitment of participants were: Avon, Aylesbury, Barnsley, Basingstoke, Bedfordshire and Hertfordshire, Cambridge and Huntingdon, Chelsmford and Colchester, Chester, Cornwall, Crewe, Cumbria, Doncaster, Dorset, East Berkshire, East Cheshire, East Devon, East of Scotland, East Suffolk, East Sussex, Gateshead, Gloucestershire, Great Yarmouth, Hereford and Worcester, Kent, Kings Lynn, Leicestershire, Liverpool, Manchester, Milton Keynes, Newcastle, North Birmingham, North East Scotland, North Lancashire, North Middlesex, North Nottingham, North of Scotland, North Tees, North Yorkshire, Nottingham, Oxford, Portsmouth, Rotherham, Sheffield, Shropshire, Somerset, South Birmingham, South East Scotland, South East Staffordshire, South Derbyshire, South Essex, South Lancashire, South West Scotland, Surrey, Warrington Halton St Helens and Knowsley, Warwickshire Solihull and Coventry, West Berkshire, West Devon, West London, West Suffolk, West Sussex, Wiltshire, Winchester, Wirral, Wycombe.

References
1. Forman D, Bray F, Brewster D, et al. eds. Cancer incidence in five continents, vol. 10. Lyon: International Agency for Research on Cancer (IARC Scientific Publication No. 164.ed.), 2014.
2. Kurman RJ, Shih IeM. Molecular pathogenesis and extravaginal origin of epithelial ovarian cancer—shifting the paradigm. *Hum Pathol* 2011;42:918–31.
3. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. *Virchows Arch* 2012;460:237–49.
4. Kurman RJ, Carcangi MJ, Herrington CS, et al., eds. WHO classification of tumours of female reproductive organs, 4th edn. Lyon: IARC, 2014.
5. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. *PLoS Med* 2008;5:e232.
6. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. *Pathology* 2011;43:420–32.
7. Cibula D, Widschwendter M, Majek O, et al. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. *Hum Reprod Update* 2011;17:55–67.
8. Rice MS, Murphy MA, Tworeger SS. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. *J Ovarian Res* 2012;5:13.
9. Sieh W, Salvador S, McGuire V, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. *Int J Epidemiol* 2013;42:579–89.
10. The Million Women Study Collaborative Group. The million women study: design and characteristics of the study population. The Million Women Study Collaborative Group. *Breast Cancer Res* 1999;1:73–80.
11. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 2003;362:419–27.
12. World Health Organization. International statistical classification of diseases and related health problems, 10th revision edn. Geneva: World Health Organization, 1990.
13. Percy C, Van Holten V, Muir CS. International classification of diseases for oncology: ICD-O-2, 2nd edn. Geneva: World Health Organization, 1990.
14. Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology: ICD-O-3, 3rd edn. Geneva: World Health Organization, 2000.
15. Shepherd JH. Revised FIGO staging for gynaecologic cancer. *Br J Obstet Gynaecol* 1989;96:889–92.
16. Travassoli FA, Devilee P, eds. World health organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs ed. Lyon: IARC Press, 2003.
17. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. *Int J Gynecol Pathol* 2000;19:7–15.
18. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. *Am J Surg Pathol* 2004;28:496–504.
19. Bodurka DC, Deavers MT, Tian C, et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a gynecologic oncology group study. *Cancer* 2012;118:3087–94.
20. Prat J, for the FIGO Committee on Gynecologic Oncology. FIGO guidelines staging classification for cancer of the ovary, fallopian tube, and peritoneum. *Int J Gynaecol Obstet* 2014;124:1–5.
21. Wilkinson N, McCluggage WG, on behalf of the Royal College of Pathologists’ Working Group on Cancer. Datasets for the histopathological reporting of neoplasms of the ovaries and fallopian tubes and primary carcinomas of the peritoneum, 3rd edn. London: Royal College of Pathologists, 2010.
22. Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality and the north ed. London: Croom Helm, 1988.
23. Lunn M, McNeill D. Applying Cox regression to competing risks. *Biometrics* 1995;51:524–32.
24. Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. *Stat Med* 1991;10:1025–35.
25. StatA Corp. StatA Statistical Software: release, 14th edn. College Station, TX: StatA Corp LP, 2015.
26. Madsen C, Baandrup L, Dehlendorf C, et al. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. *Acta Obstet Gynecol Scand* 2015;94:86–94.
27. Cibula D, Widschwendter M, Zikan M, et al. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. *Acta Obstet Gynecol Scand* 2011;90:559–63.
28. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. *J Pathol* 2001;195:451–6.

29. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. *Am J Surg Pathol* 2001;25:1283–9.

30. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. *Am J Surg Pathol* 2006;30:230–6.

31. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. *J Clin Oncol* 2007;25:3985–90.

32. Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. *Gynecol Oncol* 2008;109:168–73.

33. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. *Am J Surg Pathol* 2007;31:161–9.

34. Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclinality of synchronous ovarian and fallopian tube mucosal serous carcinoma. *Gynecol Oncol* 2008;110:408–17.

35. Gilks CB, Irving J, Kobel M, et al. Incidental non-uterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. *Am J Surg Pathol* 2015;39:357–64.

36. Morrison JC, Blanco LZ, Jr., Vang R, et al. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. *Am J Surg Pathol* 2015;39:442–53.

37. Rabban JT, Garg K, Crawford B, et al. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. *Am J Surg Pathol* 2014;38:729–42.

38. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. *J Pathol* 2010;221:49–56.

39. Singer G, Oldt R, III, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. *J Natl Cancer Inst* 2003;95:484–6.

40. Singer G, Stohr R, Cope I, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. *Am J Surg Pathol* 2005;29:218–24.

41. Li J, Abushahin N, Pang S, et al. Tubal origin of ‘ovarian’ low-grade serous carcinoma. *Mod Pathol* 2011;24:1488–99.

42. Vang R, Shih le M, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. *Histopathology* 2013;62:44–58.

43. Gram IT, Lukanova A, Brill I, et al. Cigarette smoking and risk of histological subtypes of epithelial ovarian cancer in the EPIC cohort study. *Int J Cancer* 2012;130:2204–10.

44. Kobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. *Int J Gynecol Pathol* 2010;29:203–11.

45. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. *Int J Gynecol Pathol* 2004;23:41–4.